Business Description
Adaptimmune Therapeutics PLC
NAICS : 325412
SIC : 2834
ISIN : US00653A1079
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 4.54 | |||||
Equity-to-Asset | 0.3 | |||||
Debt-to-Equity | 0.49 | |||||
Debt-to-EBITDA | -0.74 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -3.34 | |||||
Beneish M-Score | -2.69 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 120.5 | |||||
3-Year EBITDA Growth Rate | 10.3 | |||||
3-Year EPS without NRI Growth Rate | 11.6 | |||||
3-Year FCF Growth Rate | -22.2 | |||||
3-Year Book Growth Rate | -57.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 8.06 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 61.44 | |||||
9-Day RSI | 50.25 | |||||
14-Day RSI | 47.06 | |||||
6-1 Month Momentum % | -22.92 | |||||
12-1 Month Momentum % | 56.34 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.09 | |||||
Quick Ratio | 3.09 | |||||
Cash Ratio | 2.62 | |||||
Days Sales Outstanding | 7.91 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.6 | |||||
Shareholder Yield % | -14.57 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -54.47 | |||||
Net Margin % | -51.25 | |||||
FCF Margin % | -32.86 | |||||
ROE % | -96.68 | |||||
ROA % | -24.14 | |||||
ROIC % | -64.2 | |||||
3-Year ROIIC % | -11.71 | |||||
ROC (Joel Greenblatt) % | -105.91 | |||||
ROCE % | -33.28 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.78 | |||||
PB Ratio | 2.59 | |||||
Price-to-Tangible-Book | 2.98 | |||||
EV-to-EBIT | -1.59 | |||||
EV-to-EBITDA | -1.86 | |||||
EV-to-Revenue | 0.84 | |||||
EV-to-Forward-Revenue | 1.26 | |||||
EV-to-FCF | -1.77 | |||||
Price-to-Net-Current-Asset-Value | 9.94 | |||||
Earnings Yield (Greenblatt) % | -62.94 | |||||
FCF Yield % | -16.67 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Adaptimmune Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 131.421 | ||
EPS (TTM) (€) | -0.277 | ||
Beta | 2.69 | ||
Volatility % | 113.86 | ||
14-Day RSI | 47.06 | ||
14-Day ATR (€) | 0.039977 | ||
20-Day SMA (€) | 0.921 | ||
12-1 Month Momentum % | 56.34 | ||
52-Week Range (€) | 0.35 - 1.58 | ||
Shares Outstanding (Mil) | 255.75 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Adaptimmune Therapeutics PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Adaptimmune Therapeutics PLC Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Adaptimmune Therapeutics PLC Frequently Asked Questions
What is Adaptimmune Therapeutics PLC(FRA:473A)'s stock price today?
When is next earnings date of Adaptimmune Therapeutics PLC(FRA:473A)?
Does Adaptimmune Therapeutics PLC(FRA:473A) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |